Morphic Therapeutic (MORF) stock price, revenue, and financials

Morphic Therapeutic market cap is $939.7 m, and annual revenue was $3.36 m in FY 2019

$939.7 M

MORF Mkt cap, 15-Jan-2021

$7.7 M

Morphic Therapeutic Revenue Q2, 2020
Morphic Therapeutic Net income (Q2, 2020)-15.9 M
Morphic Therapeutic EBIT (Q2, 2020)-16.4 M
Morphic Therapeutic Cash, 30-Jun-2020133.1 M

Morphic Therapeutic Income Statement

Annual

USDFY, 2017FY, 2019

Revenue

3.4m

R&D expense

14.1m22.6m

General and administrative expense

2.8m5.4m

Operating expense total

16.9m28.0m

EBIT

(16.9m)(24.6m)

EBIT margin, %

(733%)

Interest income

14.0k871.0k

Pre tax profit

(16.9m)(23.8m)

Net Income

(16.9m)(23.8m)

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

5.6m5.6m7.7m

R&D expense

13.9m12.6m19.0m19.9m

General and administrative expense

2.1m2.9m4.4m4.2m

Operating expense total

16.0m15.5m23.4m24.1m

EBIT

(10.4m)(9.9m)(17.8m)(16.4m)

EBIT margin, %

(187%)(318%)(213%)

Interest expense

1.1m886.0k407.0k

Interest income

1.4m

Pre tax profit

(9.3m)(8.6m)(16.9m)(16.0m)

Income tax expense

135.0k(304.0k)(157.0k)(155.0k)

Net Income

(9.4m)(8.9m)(16.7m)(15.9m)

Morphic Therapeutic Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

20.8m185.9m101.6m

Accounts Receivable

3.5m

Prepaid Expenses

479.0k1.2m3.1m

Current Assets

21.2m187.1m243.6m

PP&E

1.7m1.8m3.4m

Total Assets

23.2m189.3m247.4m

Accounts Payable

883.0k1.7m5.2m

Short-term debt

315.0k

Current Liabilities

2.5m34.9m35.4m

Long-term debt

315.0k

Total Debt

630.0k

Total Liabilities

3.2m102.0m106.5m

Common Stock

3.0k

Preferred Stock

49.7m139.8m

Additional Paid-in Capital

661.0k1.6m238.4m

Retained Earnings

(97.5m)

Total Equity

20.0m87.3m140.9m

Financial Leverage

1.2 x2.2 x1.8 x

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

44.2m159.8m107.0m133.1m

Accounts Receivable

945.0k2.4m3.7m3.5m

Prepaid Expenses

1.4m2.9m2.9m2.5m

Current Assets

172.8m257.0m225.6m208.6m

PP&E

2.5m2.7m3.2m3.0m

Total Assets

178.6m260.1m229.2m212.0m

Accounts Payable

2.9m3.3m4.6m3.9m

Current Liabilities

43.5m26.5m36.8m45.3m

Total Liabilities

104.8m100.7m101.0m97.1m

Common Stock

3.0k3.0k3.0k

Additional Paid-in Capital

2.8m237.0m241.8m244.8m

Retained Earnings

(68.8m)(77.7m)(114.3m)(130.1m)

Total Equity

(66.0m)159.3m128.1m114.9m

Financial Leverage

-2.7 x1.6 x1.8 x1.8 x

Morphic Therapeutic Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(16.9m)(23.8m)(43.3m)

Depreciation and Amortization

434.0k539.0k821.0k

Accounts Receivable

(3.5m)

Accounts Payable

285.0k862.0k3.2m

Cash From Operating Activities

(15.4m)7.6m(41.7m)

Purchases of PP&E

(945.0k)(659.0k)(2.2m)

Cash From Investing Activities

(907.0k)(656.0k)(136.0m)

Long-term Borrowings

(333.0k)(652.0k)

Cash From Financing Activities

2.0m89.5m93.3m

Net Change in Cash

3.9m165.2m(84.3m)

Interest Paid

31.0k68.0k

Income Taxes Paid

550.0k

Quarterly

USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(14.6m)(23.5m)(16.7m)(32.6m)

Depreciation and Amortization

365.0k576.0k283.0k569.0k

Accounts Receivable

(945.0k)(2.4m)(218.0k)(64.0k)

Accounts Payable

1.2m1.5m(307.0k)(1.1m)

Cash From Operating Activities

(13.9m)(27.6m)(18.9m)(35.3m)

Purchases of PP&E

(1.1m)(1.4m)(295.0k)(385.0k)

Cash From Investing Activities

(126.0m)(91.8m)23.6m65.5m

Cash From Financing Activities

(1.8m)93.3m803.0k1.3m

Net Change in Cash

(141.7m)(26.1m)5.5m31.6m

Income Taxes Paid

550.0k480.0k480.0k

Morphic Therapeutic Ratios

USDFY, 2017

Financial Leverage

1.2 x